Please refer the attached Intimation.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transchem Limited reported its Q1 FY26 (quarter ended June 30, 2025) unaudited results on August 7, 2025. Revenue from operations was nil, same as Q1 FY25, as the company has no active operating business. Total income, which is almost entirely 'other income' (likely from investments), came in at ₹163.58 lakhs versus ₹246.97 lakhs in Q1 FY25, a drop of about 34%. Net profit for the quarter stood at ₹99.33 lakhs (₹0.81 per share), down from ₹166.21 lakhs (₹1.36 per share) in the year-ago quarter. Total expenses were modest at ₹28.48 lakhs, and there were no exceptional items. The statutory auditor, S PML & Associates, issued an unqualified limited review report with no qualifications or emphasis of matter.
The sharp YoY decline in both other income and net profit suggests weaker investment-related earnings this quarter, which could weigh on the stock. However, the company remains profitable with no debt or auditor concerns flagged, so the underlying business is stable but earnings are lumpy and dependent on investment returns.